Swayed by a discount, The National Institute of Health and Care Excellence (NICE) backflips on Sanof

Fierce Pharma ------ Just three months ago, England’s cost-effectiveness watchdogs handed down a ‘no’ on covering Sanofi 's Gaucher disease treatment Cerdelga. But they’re already singing a different tune. The National Institute of Health and Care Excellence Wednesday issued a Final Evaluation Determination on the med that backs it for long-term treatment in adults. But as usual, there’s a catch: The agency only recommends the drug when Sanofi provides it with an undisclosed, previously agreed-upon discount, or “patient access scheme.” To learn more click on the picture below to read the article.